TaiMed Biologics, founded in 2007, is a leading biopharmaceutical developer and manufacturer in Taiwan, providing extensive CDMO services and specializing in mAb development and manufacturing. Their state-of-the-art cGMP manufacturing facility is equipped with the latest technologies for upstream cell culture and downstream purification. Their CDMO division offers a comprehensive suite of services to clients, ranging from product development, analytical method development and qualification, process development and scale-up, and cGMP production of biologics. Most notably, TaiMed developed and commercially launched the first and only approved mAb for HIV treatment. This strategic integration of development capabilities with CDMO services positions TaiMed as a versatile and valuable partner in the pharmaceutical landscape.